The aim of this retrospective study on a single-institution consecutive cohort of BC patients neoadjuvantly treated outside clinical trials was to evaluate biomarkers assessed from the residual cancer burden in patients who did not achieve pCR and analyze their pre-NAT and post-NAT levels and their NAT-induced changes in relation to long-term treatment outcomes. The gene discussed is BRD2; the disease is cancer.